{"disease":{"id":"hepatocellular-injury","name":"hepatocellular injury"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03124641","title":"HOPE for Human Extended Criteria and Donation After Brain Death Donor (ECD-DBD) Liver Allografts","phase":"NA","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"University Hospital, Aachen","has_results":false},{"nct_id":"NCT03376074","title":"Interest of Oxygenated Hypothermic Perfusion (PHO) in Preservation of Hepatic Grafts From Expanded Criteria Donors","phase":"NA","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Rennes University Hospital","has_results":false},{"nct_id":"NCT02436044","title":"HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Ming Zhao","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}